Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
Florida Cancer Specialists & Research Institute, LLC (FCS) recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
The case study can be found here.1
The regimen pairs polatuzumab vedotin (Polivy) an anti-body drug conjugate, with 4 drugs from the classic chemotherapy regimen known as R-CHOP, that has long been the standard of care for these patients. Rituximab, cyclophosphamide, doxorubicin (hydroxydaunorubicin hydrochloride), and prednisone (R-CHP) are still given, but vincristine (Oncovin), is omitted in the new therapeutic combination. FDA approved the combination as a first-line treatment in DLBCL on April 19, 2023.2
FCS actively participated in the phase 1, first in-human monotherapy trial for polatuzumab vedotin, as well as the pivotal phase 3 POLARIX study that led to approval as first-line treatment.
Polatuzumab vedotin first received accelerated approval in June 2019 for use in combination with 2 other treatments. This was based on favorable findings from a phase 1 clinical trial that showed 40% of patients receiving the regimen experienced a disappearance of all signs of cancer and remained in remission for 1 year or longer.
According to the statement from FCS, its FCS Drug Development Unit was one of 13 centers taking part in the initial phase 1 first-in-human trial that took place in 2011-2012 to evaluate the drug’s effectiveness.
“The observations that we made in this initial trial were the first steps to determining what is now part of standard of care for first line patients,” said Manish R. Patel, MD, FCS director of drug development. “It is rewarding to see the impact of our work in developing this drug.”
Gustavo Fonseca, MD, FACP, FCS director of clinical research, patients in the Phase 3 study achieved rapid and sustained improvements. “Patients in the study showed improvements in quality of life, functional status and the lymphoma-associated symptoms,” Fonseca said. “There are other persistent benefits from the patient perspective as well.”
FCS offers more than 300 clinical trials at 3 phase 1 units and 37 clinic locations across Florida. “We remain at the forefront of medical discoveries of new therapies and technologies that are continuing to provide new hope for patients,” Fonseca said in the statement.
Patel was a co-author of an abstract involving the phase 1 study assessing the safety and activity of polatuzumab vedotin,3 and Patel and Fonseca presented abstracts detailing the breakthrough findings at the American Society of Hematology 64th Annual meeting and Exposition in December 2022.4,5
Gordan Joins Mukherjee at ION Exchange Keynote
FCS President and Managing PhysicianLucio Gordan, MD, took part in a keynote session with Pulitzer Prize-winning author, medical oncologist, biologist, and Rhodes ScholarSiddhartha Mukherjee, MD, at the ION Exchange 2023, held May 5-6 in San Diego, according to a statement from the practice. Mukherjee’s 2011 book, The Emperor of all Maladies, traced the knowledge of cancer and received the 2011 Pulitzer Prize for Nonfiction.
ION Exchange 2023 this week in San Diego who will share the latest clinical, operational and business insights to advance the quality of cancer care in community settings. According to a statement from FCS, they discussed discuss developments in oncology that result from ongoing discoveries in the understanding of genomics, as well as the important role that community-based providers will continue to play in the delivery of high-quality cancer care. FCS’ centralized pathology laboratory features next-generation sequencing testing capabilities that support physicians across the practice’s nearly 100 locations.
“Breakthroughs in the science of genetics are transforming our ability to deliver truly personalized cancer care,” Gordan said. “Dr Mukherjee offers a wealth of knowledge when it comes to furthering our understanding of the cancer biology and how future discoveries will continue to evolve the role of genetics leading to transformative innovations in oncology care.”
References
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Breast Cancer Treatment Disparities Impact Survival Based on Race, Age, Socioeconomics
May 9th 2024A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, highlighting the need for interventions to improve access and reduce disparities.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More